Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study
| Autor: | Shiro Imokawa, Naoki Inui, Yusuke Kaida, Yuzo Suzuki, Koji Nishimoto, Kazuhiro Asada, Masato Karayama, Hiroyuki Matsuda, Nao Inami, Tomoyuki Fujisawa, Takafumi Suda, Hironao Hozumi, Hideki Yasui, Yutaro Nakamura, Masato Fujii, Kazuki Furuhashi, Shun Matsuura, Noriyuki Enomoto, Takashi Matsui, Mikio Toyoshima |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Oncology Male Cancer Research medicine.medical_specialty Lung Neoplasms Bevacizumab Phases of clinical research Antineoplastic Agents Docetaxel Kaplan-Meier Estimate Pemetrexed Maintenance Chemotherapy 03 medical and health sciences 0302 clinical medicine Maintenance therapy Internal medicine Carcinoma Non-Small-Cell Lung Antineoplastic Combined Chemotherapy Protocols medicine Humans Lung cancer Aged Neoplasm Staging business.industry Induction chemotherapy Hematology General Medicine Induction Chemotherapy Middle Aged medicine.disease 030104 developmental biology Treatment Outcome 030220 oncology & carcinogenesis Female Taxoids Cisplatin business Febrile neutropenia medicine.drug |
| Zdroj: | Medical oncology (Northwood, London, England). 35(7) |
| ISSN: | 1559-131X |
| Popis: | Switch maintenance therapy, using alternative agents that were not administered during induction chemotherapy, is a treatment option for advanced non-squamous non-small cell lung cancer (NSCLC). Bevacizumab is known to increase the efficacy of other chemotherapeutic agents; however, switch maintenance therapy with docetaxel and bevacizumab has not been adequately studied. The goal of this study was to evaluate the efficacy and safety of switch maintenance therapy with docetaxel and bevacizumab following induction therapy with cisplatin, pemetrexed, and bevacizumab. Chemotherapy-naive non-squamous NSCLC patients received induction therapy of four cycles of cisplatin (75 mg/m2), pemetrexed (500 mg/m2), and bevacizumab (15 mg/kg). Patients who achieved disease control after induction therapy then received maintenance therapy with docetaxel (50 mg/m2) and bevacizumab (15 mg/kg) until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival from enrollment. This study enrolled 49 NSCLC patients, among which 38 (77.6%) completed the four cycles of induction therapy and received maintenance therapy. The median progression-free survival from enrollment was 7.8 months (95% confidence interval: 4.7–11.0 months). The most common toxicities of grade 3 or higher were neutropenia (68.4%), leukopenia (50.0%), febrile neutropenia (31.8%), and hypertension. Switch maintenance therapy with docetaxel and bevacizumab following induction therapy with cisplatin, pemetrexed, and bevacizumab demonstrated modest efficacy and frequent hematologic toxicity in non-squamous NSCLC patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink